The Impact of Post-Analytical Tools on New York Screening for Krabbe Disease and Pompe Disease

Abstract

by Monica M. Martin,Ryan Wilson,Michele Caggana andJoseph J. Orsini
Int. J. Neonatal Screen. 2020, 6(3), 65; https://doi.org/10.3390/ijns6030065 - 15 FEB 2022
Cited by 10 | Viewed by 2847
Abstract
New York uses a two-tier assay to screen newborns for Krabbe disease and Pompe disease. Individual enzyme activities are measured in the first-tier, and specimens from newborns with low activity are reflexed to second tier Sanger sequencing of the associated gene. Using only this two-tiered approach, the screen positive and false positive rates were high. In this study, we added an additional step that examines the activity of four additional lysosomal enzymes. Results for all enzymes are integrated using the multivariate pattern recognition software called Collaborative Laboratory Integrated Reports (CLIR) to assess the risk for disease. Results after one year of screening using the new algorithm are compared to the prior year of screening without consideration of the additional enzymes and use of CLIR. With CLIR the number of babies referred for Krabbe disease was reduced by almost 80% (from 48 to 10) and the number of babies referred for Pompe disease was reduced by almost 32% (22 to 15). Full article
(This article belongs to the Special Issue CLIR Applications for Newborn Screening)
18 pages, 2515 KiB
Open AccessArticle